Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 23298840.
- Also identified by DOI 10.1172/JCI67203 and PMC identifier 3561828.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CLINICAL VIGNETTE: A 48-year-old man with chronic kidney disease stage five due to type II diabetes mellitus and hypertension was referred for hemodialysis initiation. His physical exam showed a blood pressure of 150/80, normal fundi, a positive fourth heart sound (S4), and trace pedal edema. Moderate aortic calcification was present on prior chest X-ray. The ECG showed left ventricle hypertrophy by voltage and slight prolongation of the QT interval. Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder. What additional therapy should be initiated to reduce vascular calcifications and cardiovascular mortality?
Medical subject headings
- Cardiovascular Diseases
- Renal Insufficiency, Chronic